Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Cerilliant
Julphar
Queensland Health
Johnson and Johnson
Mallinckrodt
Harvard Business School
US Department of Justice
AstraZeneca
US Army

Generated: October 20, 2017

DrugPatentWatch Database Preview

Details for Patent: 9,295,652

« Back to Dashboard

Which drugs does patent 9,295,652 protect, and when does it expire?


Patent 9,295,652 protects DORYX MPC and is included in one NDA.

Summary for Patent: 9,295,652

Title:Controlled release doxycycline
Abstract: The disclosure provides controlled release compositions comprising tetracyclines and in some embodiments, doxycycline. The controlled release doxycycline compositions of the invention exhibit a superior dissolution profile and provide reduce side effects such as nausea and irritation.
Inventor(s): Lukas; Stefan (Manningham, AU), Lepore; Angelo (Rostrevor, AU), Mudge; Stuart (Northcote, AU)
Assignee: Mayne Pharma International Pty. Ltd. (Salisbury South, AU)
Application Number:14/521,998
Patent Claim Types:
see list of patent claims

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Mayne Pharma
DORYX MPC
doxycycline hyclate
TABLET, DELAYED RELEASE;ORAL050795-007May 20, 2016RXYesNo► Subscribe► SubscribeY TO TREAT OR PREVENT INFECTIONS CAUSED BY SUSCEPTIBLE BACTERIA USING DELAYED-RELEASE TABLETS CONSISTING OF DOXYCYCLINE HYCLATE COATED PELLETS IN A TABLET
Mayne Pharma
DORYX MPC
doxycycline hyclate
TABLET, DELAYED RELEASE;ORAL050795-008May 20, 2016RXYesYes► Subscribe► SubscribeY TO TREAT OR PREVENT INFECTIONS CAUSED BY SUSCEPTIBLE BACTERIA USING DELAYED-RELEASE TABLETS CONSISTING OF DOXYCYCLINE HYCLATE COATED PELLETS IN A TABLET
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 9,295,652

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,446,057Controlled release doxycycline► Subscribe
9,511,031Controlled release doxycycline► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Merck
Argus Health
Express Scripts
Covington
Mallinckrodt
Novartis
Healthtrust
Queensland Health
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot